Levothyroxine absorption test – Results and follow up of patients from a single center

Introduction: Treating primary hypothyroidism with appropriate weight-based dosing is usually straightforward. When supraphysiologic doses of thyroxine are required, it is important to know the reason behind the increased requirement. When compliance with medication is assured and when there are no...

Full description

Bibliographic Details
Main Authors: Karthik Subramaniam, Tom Babu, K C Sreevalsan, Shemy Mathew
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2023-01-01
Series:Indian Journal of Endocrinology and Metabolism
Subjects:
Online Access:http://www.ijem.in/article.asp?issn=2230-8210;year=2023;volume=27;issue=1;spage=32;epage=36;aulast=Subramaniam
_version_ 1797824332607520768
author Karthik Subramaniam
Tom Babu
K C Sreevalsan
Shemy Mathew
author_facet Karthik Subramaniam
Tom Babu
K C Sreevalsan
Shemy Mathew
author_sort Karthik Subramaniam
collection DOAJ
description Introduction: Treating primary hypothyroidism with appropriate weight-based dosing is usually straightforward. When supraphysiologic doses of thyroxine are required, it is important to know the reason behind the increased requirement. When compliance with medication is assured and when there are no drug interactions resulting in increased thyroxine requirements, a levothyroxine absorption test (LT4AT) could be performed to diagnose the coexistence of malabsorption. Materials and Methods: This was a single-center, retrospective chart review. Patients who had undergone LT4AT between 2018 and 2020 with a complete evaluation and follow-up records were reviewed. LT4AT and further evaluation (if necessary) were standardized, and details until the last review were obtained. Results: In all, 11 patients had complete records and follow-up details. The median age (range) of the cohort was 24 years (19 to 46), and the duration of hypothyroidism was 8 years (4 to 24). Seven had low absorption (<60%) in LT4AT of which two each had celiac disease and Helicobacter pylori infection; one had autoimmune gastritis, and in two the reasons of malabsorption was not known. The median follow-up duration was 13 months. Nine of 11 (81%) achieved euthyroid state with/without thyroxine dose reduction on follow-up. Conclusion: A high proportion of patients requiring supraphysiological doses of levothyroxine had occult malabsorptive states, some of which were curable. Even in those with pseudo-malabsorption, LT4AT helped in reinforcing compliance and thereby thyroxine dose reduction.
first_indexed 2024-03-13T10:37:26Z
format Article
id doaj.art-c60da9074ee44088bae37efdee3b8957
institution Directory Open Access Journal
issn 2230-8210
language English
last_indexed 2024-03-13T10:37:26Z
publishDate 2023-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Indian Journal of Endocrinology and Metabolism
spelling doaj.art-c60da9074ee44088bae37efdee3b89572023-05-18T05:47:05ZengWolters Kluwer Medknow PublicationsIndian Journal of Endocrinology and Metabolism2230-82102023-01-01271323610.4103/ijem.ijem_188_21Levothyroxine absorption test – Results and follow up of patients from a single centerKarthik SubramaniamTom BabuK C SreevalsanShemy MathewIntroduction: Treating primary hypothyroidism with appropriate weight-based dosing is usually straightforward. When supraphysiologic doses of thyroxine are required, it is important to know the reason behind the increased requirement. When compliance with medication is assured and when there are no drug interactions resulting in increased thyroxine requirements, a levothyroxine absorption test (LT4AT) could be performed to diagnose the coexistence of malabsorption. Materials and Methods: This was a single-center, retrospective chart review. Patients who had undergone LT4AT between 2018 and 2020 with a complete evaluation and follow-up records were reviewed. LT4AT and further evaluation (if necessary) were standardized, and details until the last review were obtained. Results: In all, 11 patients had complete records and follow-up details. The median age (range) of the cohort was 24 years (19 to 46), and the duration of hypothyroidism was 8 years (4 to 24). Seven had low absorption (<60%) in LT4AT of which two each had celiac disease and Helicobacter pylori infection; one had autoimmune gastritis, and in two the reasons of malabsorption was not known. The median follow-up duration was 13 months. Nine of 11 (81%) achieved euthyroid state with/without thyroxine dose reduction on follow-up. Conclusion: A high proportion of patients requiring supraphysiological doses of levothyroxine had occult malabsorptive states, some of which were curable. Even in those with pseudo-malabsorption, LT4AT helped in reinforcing compliance and thereby thyroxine dose reduction.http://www.ijem.in/article.asp?issn=2230-8210;year=2023;volume=27;issue=1;spage=32;epage=36;aulast=Subramaniamceliac diseasegastritishelicobacter pylorihypothyroidismpseudo-malabsorption
spellingShingle Karthik Subramaniam
Tom Babu
K C Sreevalsan
Shemy Mathew
Levothyroxine absorption test – Results and follow up of patients from a single center
Indian Journal of Endocrinology and Metabolism
celiac disease
gastritis
helicobacter pylori
hypothyroidism
pseudo-malabsorption
title Levothyroxine absorption test – Results and follow up of patients from a single center
title_full Levothyroxine absorption test – Results and follow up of patients from a single center
title_fullStr Levothyroxine absorption test – Results and follow up of patients from a single center
title_full_unstemmed Levothyroxine absorption test – Results and follow up of patients from a single center
title_short Levothyroxine absorption test – Results and follow up of patients from a single center
title_sort levothyroxine absorption test results and follow up of patients from a single center
topic celiac disease
gastritis
helicobacter pylori
hypothyroidism
pseudo-malabsorption
url http://www.ijem.in/article.asp?issn=2230-8210;year=2023;volume=27;issue=1;spage=32;epage=36;aulast=Subramaniam
work_keys_str_mv AT karthiksubramaniam levothyroxineabsorptiontestresultsandfollowupofpatientsfromasinglecenter
AT tombabu levothyroxineabsorptiontestresultsandfollowupofpatientsfromasinglecenter
AT kcsreevalsan levothyroxineabsorptiontestresultsandfollowupofpatientsfromasinglecenter
AT shemymathew levothyroxineabsorptiontestresultsandfollowupofpatientsfromasinglecenter